Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T65197
|
||||
Former ID |
TTDS00144
|
||||
Target Name |
Erythropoietin Receptor
|
||||
Gene Name |
EPOR
|
||||
Synonyms |
EPO-R; Full-length form; EPOR
|
||||
Target Type |
Successful
|
||||
Disease | Anemia [ICD9: 280-285; ICD10: D50-D64] | ||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Diabetic retinopathy [ICD9: 250.5; ICD10: H36, E10.3, E11.3, E13.3] | |||||
Emesis; Kidney transplant rejection [ICD9:787, 996.81; ICD10: R11, T86.1] | |||||
Hematological disease [ICD10: D50-D89] | |||||
Function |
Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
|
||||
BioChemical Class |
Type I cytokine receptor
|
||||
Target Validation |
T65197
|
||||
UniProt ID | |||||
Sequence |
MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL SDGPYSNPYENSLIPAAEPLPPSYVACS |
||||
Drugs and Mode of Action | |||||
Drug(s) | Darbepoetin alfa | Drug Info | Approved | Anemia | [537115] |
Epoetin alfa | Drug Info | Approved | Anemia | [538380] | |
Methoxy polyethylene glycol-epoetin beta | Drug Info | Approved | Emesis; Kidney transplant rejection | [529282], [551871] | |
RHuEPO | Drug Info | Approved | Cancer | [546426], [551871] | |
Epoetin zeta | Drug Info | Phase 3 | Anemia | [529265] | |
ErepoXen | Drug Info | Phase 3 | Anemia | [549217] | |
Hematide | Drug Info | Phase 3 | Anemia | [551985] | |
GlycoPEGylated erythropoietin | Drug Info | Discontinued in Phase 2 | Cancer | [547682] | |
Albupoietin | Drug Info | Terminated | Anemia | [547579] | |
Inhibitor | 3,5 DIBROMOTYROSINE | Drug Info | [551374] | ||
Modulator | Albupoietin | Drug Info | [549799] | ||
EPO peptide mimetics | Drug Info | [543465] | |||
EPO-derived peptide | Drug Info | [543465] | |||
Epoetin zeta | Drug Info | [529757] | |||
GlycoPEGylated erythropoietin | Drug Info | [544013] | |||
Nova-EPO | Drug Info | [543465] | |||
PharmaPEG-EPO | Drug Info | [543465] | |||
Stimulator | BBT-009 | Drug Info | [543465] | ||
BBT-021 | Drug Info | [543465] | |||
Erythropoietin | Drug Info | [543465] | |||
P-1116 | Drug Info | [543465] | |||
PEG-EPO | Drug Info | [543465] | |||
PT-401 | Drug Info | [543465] | |||
RHuEPO | Drug Info | [543465] | |||
Agonist | Darbepoetin alfa | Drug Info | [534882] | ||
Epoetin alfa | Drug Info | [535660], [537090] | |||
ErepoXen | Drug Info | [528354] | |||
Hematide | Drug Info | [531837], [532210], [537308] | |||
Activator | Methoxy polyethylene glycol-epoetin beta | Drug Info | [529282] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
PI3K-Akt signaling pathway | |||||
Jak-STAT signaling pathway | |||||
Hematopoietic cell lineage | |||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
Pathway Interaction Database | Signaling events mediated by Stem cell factor receptor (c-Kit) | ||||
EPO signaling pathway | |||||
WikiPathways | EPO Receptor Signaling | ||||
References | |||||
Ref 529265 | Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008 Mar;24(3):625-37. | ||||
Ref 537115 | Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. | ||||
Ref 538380 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (BLA) 103951. | ||||
Ref 546426 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008056) | ||||
Ref 547579 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017518) | ||||
Ref 547682 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018390) | ||||
Ref 549217 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033828) | ||||
Ref 528354 | Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83. | ||||
Ref 529757 | Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28. | ||||
Ref 531837 | Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events. Exp Hematol. 2012 Jul;40(7):575-87. | ||||
Ref 534882 | A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9. | ||||
Ref 535660 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
Ref 537090 | 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12. | ||||
Ref 537308 | Anemia in chronic kidney disease: status of new therapies. Curr Opin Nephrol Hypertens. 2009 Mar;18(2):112-5. | ||||
Ref 543465 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.